ArticleJournal for immunotherapy of cancer2021

Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.